191 related articles for article (PubMed ID: 31248974)
1. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
Falgàs A; Pallarès V; Unzueta U; Céspedes MV; Arroyo-Solera I; Moreno MJ; Sierra J; Gallardo A; Mangues MA; Vázquez E; Villaverde A; Mangues R; Casanova I
Haematologica; 2020 Mar; 105(3):741-753. PubMed ID: 31248974
[TBL] [Abstract][Full Text] [Related]
2. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
3. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4
Céspedes MV; Unzueta U; Álamo P; Gallardo A; Sala R; Casanova I; Pavón MA; Mangues MA; Trías M; López-Pousa A; Villaverde A; Vázquez E; Mangues R
Nanomedicine; 2016 Oct; 12(7):1987-1996. PubMed ID: 27085904
[TBL] [Abstract][Full Text] [Related]
4. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4
Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I
Biomed Pharmacother; 2022 Jun; 150():112940. PubMed ID: 35421785
[TBL] [Abstract][Full Text] [Related]
5. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
Lugtenburg P; Avivi I; Berenschot H; Ilhan O; Marolleau JP; Nagler A; Rueda A; Tani M; Turgut M; Osborne S; Smith R; Pfreundschuh M
Haematologica; 2017 Nov; 102(11):1913-1922. PubMed ID: 28935843
[TBL] [Abstract][Full Text] [Related]
8. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
9. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma.
Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; León X; Alba-Castellón L; Mangues R
J Exp Clin Cancer Res; 2022 Feb; 41(1):49. PubMed ID: 35120582
[TBL] [Abstract][Full Text] [Related]
10. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccines for aggressive B-cell lymphoma.
Xu-Monette ZY; Young KH
Leuk Lymphoma; 2020 Dec; 61(13):3038-3051. PubMed ID: 32840404
[TBL] [Abstract][Full Text] [Related]
12. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
13. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4
Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; Mangues R; Alba-Castellón L; León X
Acta Pharm Sin B; 2022 May; 12(5):2578-2591. PubMed ID: 35646535
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
15. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
16. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
Xu ZZ; Shen JK; Zhao SQ; Li JM
Leuk Lymphoma; 2018 Jun; 59(6):1451-1460. PubMed ID: 28952842
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
19. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
20. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Coiffier B; Salles G
Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
[No Abstract] [Full Text] [Related]
[Next] [New Search]
